|
Market Closed -
Nasdaq
04:00:00 31/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 8.900 USD | +1.14% |
|
+8.14% | +33.07% |
| 10-07 | Harvard Bioscience, Inc. Announces Creation of Scientific Advisory Board | CI |
| 08-12 | Harvard Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Harvard Bioscience, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 287.7 | 115.4 | 228.4 | 92.03 | 29.81 | 40.52 | - |
| Change | - | -59.89% | 97.92% | -59.7% | -67.6% | 35.89% | - |
| Enterprise Value (EV) | 287.7 | 115.4 | 228.4 | 92.03 | 29.81 | 40.52 | 40.52 |
| Change | - | -59.89% | 97.92% | -59.7% | -67.6% | 35.89% | 0% |
| P/E | -705x | -12x | -66.9x | -7.54x | -0.52x | -4.58x | -19.1x |
| PBR | 3.65x | 1.64x | 3.18x | 1.47x | 2.16x | 6.05x | 8.48x |
| PEG | - | -0x | 1x | -0x | -0x | 0.1x | 0.3x |
| Capitalization / Revenue | 2.42x | 1.02x | 2.03x | 0.98x | 0.34x | 0.45x | 0.43x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 0.45x | 0.43x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 4.66x | 4.77x |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 6.43x | 4.5x |
| EV / FCF | 0x | -0x | 0x | -0x | 0x | -50.6x | 22.5x |
| FCF Yield | 0.02% | -0.38% | 5.36% | -1.31% | 18.3% | -1.97% | 4.44% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.1 | -2.3 | -0.8 | -2.8 | -12.8 | -1.945 | -0.465 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 118.9 | 113.3 | 112.2 | 94.14 | 86.55 | 89.8 | 94.55 |
| EBITDA 1 | 18.5 | 10.84 | 14.55 | 7.196 | 8.081 | 8.7 | 8.5 |
| EBIT 1 | 16.72 | 9.497 | 13.11 | 5.294 | 6.163 | 6.3 | 9 |
| Net income 1 | -0.288 | -9.516 | -3.415 | -12.4 | -56.7 | -8.9 | -2.2 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 70.500 | 27.700 | 53.500 | 21.100 | 6.688 | 8.900 | 8.900 |
| Nbr of stocks (in thousands) | 4,081 | 4,166 | 4,269 | 4,362 | 4,458 | 4,552 | - |
| Announcement Date | 8/3/22 | 9/3/23 | 7/3/24 | 12/3/25 | 12/3/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.58x | - | - | - | 40.52M | |
| 35.69x | 6.07x | 23.2x | 0.27% | 258B | |
| 36.92x | 7x | 21.93x | 0.62% | 163B | |
| 49.76x | 12.05x | 25.86x | -.--% | 150B | |
| 17x | 3.45x | 11.22x | -.--% | 60.84B | |
| 36.47x | 7.31x | 23.11x | -.--% | 53.03B | |
| 21x | 2.51x | 12.66x | 2.4% | 53.31B | |
| 34.07x | 6.75x | 22.92x | 0.59% | 49.3B | |
| 47.92x | 11.82x | 26.05x | -.--% | 50.67B | |
| 81x | 7.7x | 23.37x | -.--% | 45.46B | |
| Average | 35.53x | 7.18x | 21.15x | 0.43% | 88.35B | |
| Weighted average by Cap. | 39.12x | 7.39x | 22.11x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- HBIO Stock
- Valuation Harvard Bioscience, Inc.
Select your edition
All financial news and data tailored to specific country editions
